Cargando…

Pheochromocytoma and Paraganglioma: From Treatment to Follow-up

Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors arising from chromaffin cells in the adrenal medulla, sympathetic or parasympathetic ganglia. Currently, the only curative treatment option of pheochromocytomas/paraganglioma (PPGL) is surgical resection. Surgery aims to...

Descripción completa

Detalles Bibliográficos
Autores principales: Aygun, Nurcihan, Uludag, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751245/
https://www.ncbi.nlm.nih.gov/pubmed/33364876
http://dx.doi.org/10.14744/SEMB.2020.58998
_version_ 1783625631221678080
author Aygun, Nurcihan
Uludag, Mehmet
author_facet Aygun, Nurcihan
Uludag, Mehmet
author_sort Aygun, Nurcihan
collection PubMed
description Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors arising from chromaffin cells in the adrenal medulla, sympathetic or parasympathetic ganglia. Currently, the only curative treatment option of pheochromocytomas/paraganglioma (PPGL) is surgical resection. Surgery aims to eliminate both risks of hypersecretion and tumor growth. The consequences of hypersecretion should be carefully controlled with medical therapy before and during the surgery. Postoperative major complications are hypotension and rebound hypoglycemia, and patients should be followed closely for 24-48 hours. The choice of surgical approach is determined based on multiple factors, including germline genetic test results, the size of the tumor, body mass index, surgeon’s experience, and the likelihood of malignancy. Primary tumor resection does not completely eliminate the risk of tumor persistence and recurrence. Therefore, all patients with PPGL who are surgically treated should be followed for at least 10 years for recurrent disease and new tumor formation. Although surgical resection is the only curative treatment for PPGLs, surgical treatment is palliative except for resectable locoregional metastases in metastatic disease or for isolated distant metastases. The purpose of palliative treatment is to reduce hormone secretion and prevent metastasis-related complications in a critical anatomical location Combined and alfa;- and beta- adrenergic blockade is usually applied in patients with PPGL preoperatively. Some patients may present with pheochromocytoma multisystem crisis, which is a life-threatening condition that can involve cardiovascular, pulmonary, neurological, gastrointestinal, renal, hepatic and metabolic systems. Pheochromocytoma crisis may be spontaneous or may present with the tumor manipulation, trauma, corticosteroids, beta-blockers, anesthetic drugs, and the stimulation of non-adrenal surgical stress. These patients should be considered as medical emergencies rather than surgical emergencies. In this review, it was aimed to evaluate the pre-, per and post-operative management, curative and palliative surgical management, and postoperative outcomes and follow-up of the patients with PPGLs.
format Online
Article
Text
id pubmed-7751245
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-77512452020-12-22 Pheochromocytoma and Paraganglioma: From Treatment to Follow-up Aygun, Nurcihan Uludag, Mehmet Sisli Etfal Hastan Tip Bul Review Pheochromocytomas (PCC) and paragangliomas (PGL) are rare neuroendocrine tumors arising from chromaffin cells in the adrenal medulla, sympathetic or parasympathetic ganglia. Currently, the only curative treatment option of pheochromocytomas/paraganglioma (PPGL) is surgical resection. Surgery aims to eliminate both risks of hypersecretion and tumor growth. The consequences of hypersecretion should be carefully controlled with medical therapy before and during the surgery. Postoperative major complications are hypotension and rebound hypoglycemia, and patients should be followed closely for 24-48 hours. The choice of surgical approach is determined based on multiple factors, including germline genetic test results, the size of the tumor, body mass index, surgeon’s experience, and the likelihood of malignancy. Primary tumor resection does not completely eliminate the risk of tumor persistence and recurrence. Therefore, all patients with PPGL who are surgically treated should be followed for at least 10 years for recurrent disease and new tumor formation. Although surgical resection is the only curative treatment for PPGLs, surgical treatment is palliative except for resectable locoregional metastases in metastatic disease or for isolated distant metastases. The purpose of palliative treatment is to reduce hormone secretion and prevent metastasis-related complications in a critical anatomical location Combined and alfa;- and beta- adrenergic blockade is usually applied in patients with PPGL preoperatively. Some patients may present with pheochromocytoma multisystem crisis, which is a life-threatening condition that can involve cardiovascular, pulmonary, neurological, gastrointestinal, renal, hepatic and metabolic systems. Pheochromocytoma crisis may be spontaneous or may present with the tumor manipulation, trauma, corticosteroids, beta-blockers, anesthetic drugs, and the stimulation of non-adrenal surgical stress. These patients should be considered as medical emergencies rather than surgical emergencies. In this review, it was aimed to evaluate the pre-, per and post-operative management, curative and palliative surgical management, and postoperative outcomes and follow-up of the patients with PPGLs. Kare Publishing 2020-12-11 /pmc/articles/PMC7751245/ /pubmed/33364876 http://dx.doi.org/10.14744/SEMB.2020.58998 Text en Copyright: © 2020 by The Medical Bulletin of Sisli Etfal Hospital http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Review
Aygun, Nurcihan
Uludag, Mehmet
Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
title Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
title_full Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
title_fullStr Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
title_full_unstemmed Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
title_short Pheochromocytoma and Paraganglioma: From Treatment to Follow-up
title_sort pheochromocytoma and paraganglioma: from treatment to follow-up
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751245/
https://www.ncbi.nlm.nih.gov/pubmed/33364876
http://dx.doi.org/10.14744/SEMB.2020.58998
work_keys_str_mv AT aygunnurcihan pheochromocytomaandparagangliomafromtreatmenttofollowup
AT uludagmehmet pheochromocytomaandparagangliomafromtreatmenttofollowup